Actively Recruiting
TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-02-24
100
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This multi-center study aims to study the efficacy of TPO-RAs' transformation in Chinese ITP patients older than 14 years. This study will be conducted in ITP patients who had not responded to first-line in the previous treatment .
CONDITIONS
Official Title
TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women 14 years of age or older
- Diagnosed with primary immune thrombocytopenia with two platelet counts below 30x10^9/L or with bleeding at least 7 days apart
- No evidence of other causes of low platelet counts like pseudothrombocytopenia or myeloid fibrosis
- Poor response to first-line treatment including up to 4 weeks of eltrombopag, herombopag, avatrombopag, or 14 days of rhTPO
- Willing and able to follow the study protocol and sign informed consent
You will not qualify if you...
- Diagnosed with secondary immune thrombocytopenia
- History of blood clots, disseminated intravascular coagulation, heart attack, stroke, thrombotic microangiopathy, autoimmune diseases, cancer, liver cirrhosis, or other serious diseases
- Liver disease with total bilirubin or liver enzymes 2 times above normal, or kidney disease with creatinine 1.5 times above normal
- Allergic to eltrombopag, herombopag, rh-TPO, avatrombopag, or any ingredients
- Used rituximab in the past 3 months
- Had splenectomy in the past 3 months
- Deemed unsuitable for the study by the researcher
- Pregnant or planning pregnancy in the near future
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
W
Wei Liu
CONTACT
L
Lei Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here